Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium

Introduction: We sought to describe the incidence, risk factors, and survival outcomes associated with pathologic upstaging from non-muscle invasive bladder cancer (NMIBC) to muscle invasive bladder cancer (MIBC) after robot-assisted radical cystectomy (RARC). Methods: We reviewed the International Robotic Cystectomy Consortium database between 2004 and 2020. Upstaging was defined as >= pT(2) or pathologic node positive (pN+) at final pathology analysis from clinical = 3; 55% vs 44%, p=0.04), and had higher rate of preoperative hydronephrosis (26% vs 10%, p<0.01). They were more likely to have positive surgical margins (10% vs 3%, p=0.01), recurrences (28% vs 9%, p<0.01), and to receive adjuvant/salvage treatment (26% vs 3%, p<0.01). On multivariate analysis, upstaging was associated with older age (odds ratio [OR] 1.04; confidence interval [CI] 1.01-1.07, p<0.01), cT(1)vs cTis (OR 4.25; CI 1.57-11.48, p<0.01), cT(1)vs cTa (OR 2.92; CI 1.40-6.06, p<0.01), and preoperative hydronephrosis (OR 3.18; CI 1.60-6.32, p<0.01). Upstaged patients had worse 5-year RFS (53% vs 85%, log rank p<0.01), DSS (66% vs 93%, log rank p<0.01), and OS (49% vs 74%, log rank p<0.01). The rate of upstaging did not significantly change over time (38% in 2004 to 27% in 2019, p=0.17). Conclusion: Upstaging to MIBC occurred in a significant proportion of patients after RARC for NMIBC and was associated with worse survival outcomes. Older patients, those with cT(1) disease and hydronephrosis were more likely to upstage.